The effect of crocin in multiple sclerosis patients

The effect of crocin on biomarkers of oxidative stress in the Saliva and Urine of patients with multiple sclerosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016122013194N3

Enrollment

Registered

2017-03-05

Start date

2051-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Multiple sclerosis. Condition 2: Multiple sclerosis. Condition 3: Multiple sclerosis. Other acute disseminated demyelination Multiple sclerosis Other demyelinating diseases of central nervous system

Interventions

Intervention 1: In the control group a placebo (a capsule that is not crocin of saffron, but the patients are not told anything about it) two capsules a day for 15 days to receive oraly. Intervention

Placebo

Treatment - Drugs

In the control group a placebo (a capsule that is not crocin of saffron, but the patients are not told anything about it) two capsules a day for 15 days to receive oraly.

In the intervention group crocin saffron capsules of 30 mg per day (15 mg twice daily) given for 15 days.

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: inclusion criteria:Recently diagnosed relapsing-remitting MS patients; Patients between 20-40 years old exclusion criteria: Receiving corticosteroids before the study; Receiving immunomodulatory drugs such as interferons before the study; Diabetes; Underlying chronic illnesses including liver disease, kidney, lung and heart; Smoking; Pregnancy and lactation; Any rheumatologic disease or vasculitis; History of hypersensitivity to saffron

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Total antioxidant capacity of urine. Timepoint: Before and after intervention. Method of measurement: spectrophotometer TPTZ reagent in a 593 nm.;Catalase Enzyme. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Total antioxidant capacity of saliva. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Thiol groups of saliva. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Lipid peroxidation. Timepoint: Before and after intervention. Method of measurement: spectrophotometer TBA reagent in a 532 nm.;Thiol levels in urine. Timepoint: Before and after intervention. Method of measurement: HU method.	—

Measure

Time frame

Total antioxidant capacity of urine. Timepoint: Before and after intervention. Method of measurement: spectrophotometer TPTZ reagent in a 593 nm.;Catalase Enzyme. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Total antioxidant capacity of saliva. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Thiol groups of saliva. Timepoint: Before and after intervention. Method of measurement: According U / ml using Spectrophotometry.;Lipid peroxidation. Timepoint: Before and after intervention. Method of measurement: spectrophotometer TBA reagent in a 532 nm.;Thiol levels in urine. Timepoint: Before and after intervention. Method of measurement: HU method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Akram Ranjbar

Hamedan University of Medical Sciences

Akranjbar1389@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026